Forward Pharma Joins Hands With Tsinghua University Shenzhen Research Institute To Establish "Cancer Innovative Drug Research And Development Center"

Recently, the "Anti-Tumor Innovative Drug Research and Development Center" (hereafter referred to as the "R&D center") jointly established by Shenzhen Forward Pharmaceutical Co., Ltd. and Shenzhen Tsinghua University Research Institute was officially launched. The R&D center will be integrated into the overall research and development system of Shenzhen Tsinghua University Research Institute and will be under the supervision of the Institute of New Materials and Biomedicine.

The biopharmaceutical industry is one of the key strategic emerging industries for the development of Shenzhen City. The R&D center will focus on building two directed design and optimization platforms for small molecule drugs and large molecule antibody drugs. The main strategy will be rapid follow-up to carry out independent research and development of new types of anti-tumor drugs. At the same time, the R&D center will build a high-level research team and cultivate a group of professional talents in innovative drug research and development and industrialization.

The establishment of the R&D center in collaboration with the research institute is a major event in the development process of Forward Pharma. With the strong scientific research strength and outstanding social influence of Tsinghua University, it will undoubtedly provide great assistance and broader development space for Forward Pharma in the future.

Positioning of the R&D center

Relying on the industrial transformation platform of Tsinghua Research Institute, based on Forward Pharma ' independent research and source innovation capabilities, seizing the historic opportunity for the development of domestic innovative drug industry, utilizing the unique development, research and development, and industrial environment and atmosphere of Shenzhen to plan, construct, and develop this R&D center around several existing national first-class anti-tumor new drug product development pipelines. The R&D center has the following functional positioning:

Promotion of core flagship products to market

Promote the independent research and development of anti-tumor drugs to clinical trials and listing, become an important clinical field with independent core intellectual property rights flagship product, break the monopoly of imported drugs in certain anti-tumor fields, and create huge social and economic benefits while benefiting patients and national health.

Undertaking early-stage excellent projects

Relying on the independent research and development capabilities and unique innovation system of the professional team, undertake upstream early-stage research and development achievements at home and abroad, adopt market-oriented means and enterprise-based operations to incubate and mature the nascent products on this platform, and complete value transformation.

Outputting successfully incubated projects

The products successfully developed and incubated by this platform can choose to cooperate with outstanding pharmaceutical companies at home and abroad for joint development, authorize the research and development and marketing rights (License out) to partners, and adopt the international milestone model for cooperation to promote the rapid transformation of the results and achieve win-win outcomes.

Promotion of local innovative drug industry development, cultivation of professional and cutting-edge scientific research and development, industrial transformation and business operation talents

Relying on the continuous independent research and development and creativity of the platform and team, promote the development of Shenzhen, and even Guangdong's local innovative drug industry chain. At the same time, it is not only necessary to introduce international talents, it is more important to cultivate localized talents. Scientific research institutions and enterprises closely cooperate to cultivate diversified talents that meet the needs of industrial development, thereby further promoting the healthy and sustainable development of the pharmaceutical industry.

Introduction of Tsinghua Shenzhen International Graduate School

The Tsinghua Shenzhen International Graduate School (SIGS) is a Sino-foreign cooperative education institute jointly established by the Shenzhen Municipal Government and Tsinghua University, operating in an enterprise-oriented manner. The institute covers an area of 16,000 square meters and has a construction area of 32,000 square meters, and was completed and put into use in August 1999.

After ten years of development, SIGS has gradually explored the operational development model of "technology innovation incubator", established a complete "technology innovation incubation system," and formed a development driving mode of deep integration of science, technology, and finance. SIGS has invested a total of CNY 600 million to set up a technical support platform based on the trends of science, technology and industry development in Shenzhen and domestic and foreign enterprises' needs, such as the Institute of Broadband Wireless Communication, the Institute of Electronic Information Technology, the Institute of New Materials and Biomedicine, the Institute of Optoelectronics and Advanced Manufacturing, the Institute of New Energy and Environmental Technology and the Institute of Aerospace Technology. SIGS has 26 laboratories and R&D centers.

With the formation of the independent innovation incubation system, SIGS realized interaction development among six plates: R&D platform, education and training, investment incubation, innovation base, technology finance and international cooperation. Led by innovative thinking, SIGS implements enterprise-oriented management internally, and encourages and restricts mechanism effectively interacting externally. In the process of operation, SIGS adheres to market-oriented operation and strives to achieve a win-win situation among SIGS, enterprises, and the government, and has achieved good social and economic benefits.

SIGS insists on pursuing internationalization and has established five centers around the world, including the North America Innovation Center in Silicon Valley in the United States (founded in 2010); the European Center in Oxford in the United Kingdom (founded in 2011); the Russia Center in Moscow (founded in 2013); the Germany Center in Cologne (founded in 2014); and the Israel Center in Tel Aviv (founded in 2015). These centers aim to attract high-quality talents and technology projects from international, and promote domestic technological advantages to international and achieve genuine international technology transfer.